Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, hormone.

DreamPharm Products:

Lutein-20||Herbs for headache, fever, and migraine || Milk thistle||Saw palmetto|| Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract|| Ginseng and Ginkgo||Hair Million|| DHEA||Coenzyme Q10|| Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.|| Weight loss herbal formula for menopause and pms||Ginkgo biloba|| Colon cleansing, Laxative||ViaVita, Lecithin for healthy liver

Fatty acids resources:

Pathogen research abs 1 || Pathogen research abs 2 || Pathogen research abs 3 || Pathogen research abs 4 || Pathogen research abs 5 || Hormone and endocrine research abs 1 || Hormone and endocrine research abs 2 || Hormone and endocrine research abs 3 || Hormone and endocrine research abs 4 || Hormone and endocrine research abs 5

Bull Exp Biol Med. 2002 Nov;134(5):445-7.
Relative binding activity of new antigestagens with progesterone receptors in human hyperplastic endometrium.

Kamernitskii AV, Levina IS, Kareva EN, Kirpichnikova NV, Mgdesyan KK, Ovchinnikova EV.

Laboratory of Steroids and Terpenoids, Institute of Organic Chemistry, Russian Academy of Sciences, Moscow.

We determined the content and binding capacity of progesterone receptors in the endometrium of patients with adenomatous and fibroid polyps, adenocystic hyperplasia, and atypical hyperplasia before and after gestagen therapy. Hyperplasia of the endometrium was accompanied by changes in affinity of cytosolic progesterone receptors for antigestagens, which provides the possibility of individual correction of hormone therapy.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12802447&dopt=Abstract

Arch Toxicol. 2003 Jun 12 [Epub ahead of print].
Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects.

Kennel P, Pallen C, Barale-Thomas E, Espuna G, Bars R.

Bayer CropScience, Centre de Recherche de Sophia-Antipolis, BP153, 06903, Sophia-Antipolis, France.

The main objective of this 28-day oral gavage toxicity study in the rat was to investigate which of the current and/or additional parameters of the OECD Test Guideline 407 would reliably and sensitively detect the endocrine-mediated effects of the nonsteroidal antiestrogen tamoxifen. In addition, as this study was performed using two subgroups of five animals of each sex run concurrently, it enabled an assessment of the intralaboratory reproducibility while also assessing the potential value of using ten animals of each sex per group instead of using the standard five animals of each sex per group stipulated by the current guideline. Tamoxifen was administered daily by gavage to groups of 7-week-old Wistar rats for at least 28 days at dose levels of 5, 30, or 200 micro g/kg body weight. Additional parameters specified in the enhanced OECD Test Guideline 407 were spermatozoa enumeration and morphology of the cauda epididymis, hormonal analysis of the thyroid-stimulating hormone (TSH), triiodothyronine (T(3)) and thyroxine (T(4)) levels, monitoring of the estrous cycle during week 4 of treatment to ensure females were in diestrus on the day of terminal sacrifice, organ weight of ovary, uterus, thyroid gland, prostate gland (ventral and dorsolateral parts), seminal vesicles with coagulation glands and pituitary gland, and microscopic investigation of the pituitary gland, vagina, mammary gland, seminal vesicles with coagulating glands, epididymis, and prostate gland (ventral and dorsolateral parts). Overall, 200 micro g/kg per day was considered to be the Maximum Tolerated Dose (MTD) in both sexes, resulting in a marked reduction of body weight gain, together with slight effects on clinical signs, hematology, plasma chemistry, and microscopic changes in some endocrine tissues. Five micrograms per kilogram per day represented the No Observed Adverse Effect Level (NOAEL) in males and the No Observed Effect Level (NOEL) in females. At the intermediate dose level (30 micro g/kg per day), the current OECD Test Guideline 407 was appropriate to detect the specific endocrine-related changes induced by tamoxifen in females, based on the histopathology findings observed in the ovary and the uterus. The additional parameters which were found to be changed in females (thyroid hormone levels, ovary and uterus weights, and histopathology of vagina) provided supplementary information further confirming tamoxifen-mediated endocrine effects. In males, when data from the current Test Guideline 407 were considered at the intermediate dose level, specific endocrine effects were only indicated on the basis of the histopathology findings observed in the prostate gland. The additional parameters examined which were found to be changed (prostate gland and seminal vesicle weights, and histopathology of seminal vesicle and mammary gland) were necessary to confirm the specific tamoxifen-mediated endocrine effects. Hence, amongst the additional parameters contained in the enhanced OECD Test Guideline 407, organ weights and histopathological examination of endocrine-related organs were the most helpful in confirming the detection of tamoxifen-mediated endocrine effects. The reproducibility evaluation showed that a group size of five animals of each sex consistently allowed the detection of endocrine effects with the current Test Guideline in both sexes at the high dose level and in females at the intermediate dose level. Doubling the animal number from five to ten of each sex per dose level did not notably increase the sensitivity of detection of endocrine-mediated effects.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12802581&dopt=Abstract [PubMed - as supplied by publisher]

Anat Embryol (Berl). 2003 Jul;207(1):45-62. Epub 2003 Jun 11.
Placentation in the alpaca Lama pacos.

Olivera L, Zago D, Leiser R, Jones C, Bevilacqua E.

Faculty of Veterinary Medicine & Zootechnology, National University Altiplano, 291 Puno, Casilla, Peru.

Reproduction in South American camelids is poorly studied. To extend our knowledge of the development and cellular physiology of the placenta in the alpaca Lama pacos, we have examined specimens from day 150 of pregnancy to term. Morphological investigations using light, transmission and scanning electron microscopy, the histochemical localization of iron, alkaline and acid phosphatase activity, and the immunodetection of placental lactogen hormone were performed. Throughout pregnancy there was a progressive increase in the depths of folds on the uterine mucosa surface together with a thickening of the endometrium. Glandular cells exhibited PAS and acid phosphatase (AcP) positive secretion granules. In the chorion, giant trophoblast polyploid cells gradually became more numerous and larger. Non-giant cells exhibited positive granules for PAS, alkaline phosphatase (AkP) reaction and immunostaining for bovine placental lactogen hormone (PLH). SDS -PAGE electrophoresis and Western blotting procedures also confirmed the presence of a bovine PLH-like glycoprotein in the fetal alpaca placenta. Over the glandular openings, the chorion formed typical areolae, where the trophoblast exhibited AcP and PAS positive reactions. At these sites, the fetal endothelial cells contained iron-storage granules in their cytoplasm. The trophoblast-epithelial interface exhibited a complex microvillous interdigitation, in which an AkP reaction was very prominent. The chorionic capillaries progressively indented adjacent trophoblast cells. These data suggest that although the epitheliochorial alpaca placenta is diffuse, various trophoblast cell types and specialized areas of the maternofetal interface give the placenta micro-regional functions where histiotrophic nutrition, hormone production and molecular exchange are prevalent.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12802689&dopt=Abstract [PubMed - in process]

Idrugs. 2002 Aug;5(8):804-14.
Growth hormone secretagogues: Past, present and future.

Fehrentz JA, Martinez J, Boeglin D, Guerlavais V, Deghenghi R.

LAPP, UMR 5810, Faculte de Pharmacie, 15 avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France. fehrentolombes.pharma.univ-montp1.fr

Growth hormone-releasing peptides (GHRPs) or growth hormone secretagogues (GHSs) of peptide or non-peptide structure are able to stimulate growth hormone secretion. They act through a growth hormone-releasing hormone (GHRH)/somatotropin release inhibiting factor (SRIF) independent pathway. A receptor able to bind to these compounds was cloned in 1996, and a natural ligand of this receptor, named ghrelin, was characterized in 1999. The potential therapeutic value of such compounds is considerable as they offer an alternative therapy for treatment of deficiency in growth hormone secretion. As growth hormone (GH) also participates in many anabolic effects, interest in these compounds is increasing and many clinical applications are expected in the future.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12802697&dopt=Abstract [PubMed]

Idrugs. 2002 Jul;5(7):689-95.
Gastrin and gastrin receptor ligands - A review of recent patent literature.

Steel K.

The James Black Foundation Ltd, 68 Half Moon Lane, London, SE24 9JE, UK. katherine.steecl.ac.uk

The peptide hormone gastrin is involved in the regulation of acid secretion in the stomach and acts as a growth hormone in the stomach. Although gastrin receptors are expressed in many tumors throughout the body, the clinical significance of this is still unknown. Despite considerable efforts from many pharmaceutical organizations for over a decade, there is as yet no commercially available gastrin ligand. This review covers the patent literature relating both to novel gastrin ligands and to new applications of gastrin and its ligands, including gastrin antibodies, between April 1998 and April 2002.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12802702&dopt=Abstract [PubMed]

Prescription drugs, surgical hair transplantation, topical application of various oils or creams... Also prayer and wishing...
Hair Million is an alternative approach to hair loss problems. Anecdotes and personal experiences testify that it works. Hair Million shows positive results and improvement for age-related hair thinning and hair loss for a large fraction of people who take it. How does it work? Good question. The molecular biological or clinical mechanisms of action as to how Hair Million exactly works to help stop hair loss, and promote hair growth is completely unknown. The only evidences for the effecacy of Hair Million on hair growth are only anedotal and based on personal experiences. There has been no clinical trials or placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth.
That's enough for many people. Also, there are two merits in the hair restoration herbal formula:
Firstly, HairMillion is comparatively inexpensive, and secondly, it is made only of herbs that are known to be safe when consumed in regular quantities. Herbs in Hair Million are also known for cardiotonic effects, meaning that the herbs will make your heart stronger.

DHEA is a natural hormone, and it is produced in our body by the adrenal glands. DHEA has been suggested to provide numerous potential benefits. DHEA (or dehydroepiandrosterone) is converted into androgens (male hormones) or estrogens (female hormones) in the cells.

DreamPharm Online Healthy Supplements || Lutein || Progesterone Cream || Natural herbal formula for hair loss problems ||